Nadiye Sever, Emil Yunusov, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Abdussamet Çelebi, Selver Işık, İbrahim Vedat Bayoğlu, Osman Köstek, Murat Sarı
{"title":"Sex-related disparities in outcomes of survival in biliary tract cancer patients.","authors":"Nadiye Sever, Emil Yunusov, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Abdussamet Çelebi, Selver Işık, İbrahim Vedat Bayoğlu, Osman Köstek, Murat Sarı","doi":"10.1007/s00432-025-06096-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Biliary tract cancer (BTC) is a rare and aggressive cancer with a poor prognosis. Despite treatment, overall survival is less than 12 months. It is a proven fact that women have better chemotherapy responses and survival than men in almost all cancer types. We believe that gender is one of the important factors affecting the prognosis of BTC. In this study, we aimed to investigate the effect of gender on prognosis in this type of cancer.</p><p><strong>Methods: </strong>This study was designed as a single-centre retrospective analysis of patients with BTC. All patients, regardless of operability, were included in the study. Prognostic factors were analysed using univariate and multivariate analysis.</p><p><strong>Results: </strong>A total of 100 patients (48% female) were included in the study. The median follow-up time was 72.2 months (95% CI 39.3-105.0), and the median OS was 9.5 months (95% CI 5.3-13.8) for all study patients. The 72-month survival rate was 13.4%. The observed survival rates at 10.4% for male patients and 15.7% for female patients demonstrate the importance of considering gender as a prognostic factor. A multivariate analysis indicated a significant association between female gender and longer overall survival, with an adjusted hazard ratio of 0.59 (95% CI 0.38-0.92, p = 0.02).</p><p><strong>Conclusion: </strong>It is clear that female gender is associated with a better response to chemotherapy and longer survival in BTCs. These findings should be taken into account in treatment selection and prognosis predictions. Further research may help elucidate the mechanisms underlying these sex differences and help develop more effective treatments.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"95"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868355/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-025-06096-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Biliary tract cancer (BTC) is a rare and aggressive cancer with a poor prognosis. Despite treatment, overall survival is less than 12 months. It is a proven fact that women have better chemotherapy responses and survival than men in almost all cancer types. We believe that gender is one of the important factors affecting the prognosis of BTC. In this study, we aimed to investigate the effect of gender on prognosis in this type of cancer.
Methods: This study was designed as a single-centre retrospective analysis of patients with BTC. All patients, regardless of operability, were included in the study. Prognostic factors were analysed using univariate and multivariate analysis.
Results: A total of 100 patients (48% female) were included in the study. The median follow-up time was 72.2 months (95% CI 39.3-105.0), and the median OS was 9.5 months (95% CI 5.3-13.8) for all study patients. The 72-month survival rate was 13.4%. The observed survival rates at 10.4% for male patients and 15.7% for female patients demonstrate the importance of considering gender as a prognostic factor. A multivariate analysis indicated a significant association between female gender and longer overall survival, with an adjusted hazard ratio of 0.59 (95% CI 0.38-0.92, p = 0.02).
Conclusion: It is clear that female gender is associated with a better response to chemotherapy and longer survival in BTCs. These findings should be taken into account in treatment selection and prognosis predictions. Further research may help elucidate the mechanisms underlying these sex differences and help develop more effective treatments.
胆道癌(BTC)是一种罕见的恶性肿瘤,预后差。尽管接受了治疗,总生存期仍不到12个月。事实证明,在几乎所有类型的癌症中,女性都比男性有更好的化疗反应和生存率。我们认为性别是影响BTC预后的重要因素之一。在这项研究中,我们旨在探讨性别对这类癌症预后的影响。方法:本研究设计为BTC患者的单中心回顾性分析。所有患者,无论是否可操作性,均被纳入研究。采用单因素和多因素分析对预后因素进行分析。结果:共纳入100例患者,其中女性48%。所有患者的中位随访时间为72.2个月(95% CI 39.3-105.0),中位OS为9.5个月(95% CI 5.3-13.8)。72个月生存率为13.4%。观察到男性患者的生存率为10.4%,女性患者为15.7%,这表明将性别视为预后因素的重要性。一项多变量分析显示,女性性别与更长的总生存期之间存在显著关联,校正风险比为0.59 (95% CI 0.38-0.92, p = 0.02)。结论:很明显,女性与btc患者更好的化疗反应和更长的生存期有关。这些发现应考虑到治疗选择和预后预测。进一步的研究可能有助于阐明这些性别差异背后的机制,并有助于开发更有效的治疗方法。
期刊介绍:
The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.
The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.